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Abstract 
Emerging of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide 
outbreak and a major public health problem. The present review was conducted to provide brief 
information about the origin, symptoms, transmission, pathogenesis, diagnosis, and treatment of the 
virus. A search was performed in the databases of PubMed, Scopus, Science Direct, and Google scholar 
with English keywords including 2019-nCoV, Coronavirus disease 2019 (COVID-19), SARS-CoV-2, and 
novel coronavirus from December 2019 to 15 March 2020, and the search results were evaluated. 
Selected studies have shown that the virus may have originated from the bat. It has also been shown 
that the virus receptor is angiotensin-converting enzyme 2 (ACE2) which is also the SARS virus receptor 
and is expressed in most human tissues. The most common way of virus transmission was suggested 
through respiratory droplets and close contact. It is also transmitted by asymptomatic patients, but 
vertical transmission from mother to fetus has not been confirmed. Real-time reverse transcriptase 
(RT)-PCR is the gold standard for SARS-CoV-2 detection, but chest computed tomography (CT) can be 
more sensitive to detect positive cases. Since no effective vaccine or drug for prevention and treatment 
of this disease has not yet been identified and also because of the high incubation and infection period, 
easy transmission, and the lack of complete recognition of the characteristics and stability in different 
environments, the best way to control of COVID-19 is to prevent the spread of the infection in different 
ways and take seriously personal and public hygiene. 
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1. Introduction 
Coronaviruses are one of the most important 
pathogens in the human respiratory system. Severe 
Respiratory Syndrome (SARS) and Middle East 
Respiratory Syndrome (MERS) have previously been 
identified as risk factors for general health [1]. In late 
December 2019, a report was published on 
pneumonia in a group of patients with unknown 
cause, possibly related to contact with the seafood 
market in Wuhan, China [2]. In January 2020, the 
World Health Organization (WHO) temporarily 
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named this virus the 2019 novel coronavirus (2019-
nCoV). Later, in February 2020, they officially named 
it severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) [3, 4]. The coronaviruses are a class of 
coated single-stranded RNA viruses that are 
genetically and serologically subdivided into four 
subfamilies, including alpha, beta, gamma, and delta. 
In this regard, most human infections are caused by 
alpha and beta subfamilies. Phylogenetic analyses 
show that the etiology of coronavirus disease 2019 
(COVID-19), like SARS and MERS, belongs to the 
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beta-coronavirus and is now known as SARS-CoV2 
due to its high genetic similarity to SARS [1, 5, 6]. 
Reports suggest that the virus has spread to most 
countries in the world (Table 1) [7-9], and the World 
Health Organization (WHO) considers it a pandemic 
[10]. So far, no evidence of mutation has been reported 
for SARS-CoV-2, probably due to the compatibility of 
the virus with humans, which binds to its receptor 
angiotensin-converting enzyme 2 (ACE2) with very 
high affinity [11]. It is more likely that the SARS virus 
also mutated during the 2002-2004 epidemics to 
better bind and replicate to its cellular receptor and 
increased its pathogenicity [12]. In this regard, it is 
necessary to investigate clinically isolated viruses with 
more time and geographical diversity to develop and 
use appropriate prevention and treatment methods 
with full knowledge of the characteristics of the virus. 
The present study was conducted to provide an 
overview of the origin, symptoms, transmission, 
pathogenesis, diagnosis, and treatment of this virus. 
 
2. Source of virus 
Although the source of COVID-19 has not yet been 
fully clarified, epidemiological studies and pathogen 
analysis suggest that the southern Chinese seafood 
market in Wuhan may be an important source of 
infection. Although the evidenced source of this virus 
is wild animals, it has not been clarified which animal 
became infected with the virus and transmitted it to 
humans [4]. Other studies have suggested that 
COVID-19 may have originated from a coronavirus 
with bat origin. Evidence suggests a high degree of 
ACE2 receptor homology of diversity in animal species 
(except mice and rats). Thus, these animal species may 
be considered as intermediate hosts or animal models 
for COVID-19 infection. Also, these viruses have an 
open reading frame (ORF) and intact on gene 8, which 
is another indicator for coronaviruses with bat origin 
[1, 13]. Also, the genomic analysis of viruses isolated 
from patients has a similarity of 96.2% to 
coronaviruses isolated from bats [14]. Nevertheless, 
the source of the infection has not been completely 
recognized and more studies are needed in the future 
in this regard. 
 
3. Ways of virus transmission 
The main way for transmission of the virus is the 
transmission of respiratory droplets and close contact 
with patients suffering from coronary pneumonia. 
Studies suggest that the pathogen can also be isolated 
from patients’ feces and urine. In infected people, 
respiratory droplets contain a large number of 
infectious agents that enter the environment through 
coughing and sneezing. The spread of respiratory 
droplets is unlikely without the help of environmental 
conditions [15]. Rather, the transmission of this virus 
is more likely to occur in crowded and poorly 
ventilated public places such as conference rooms, 
restaurants, stations, public transportation, elevators, 
and temporary shelters. There are usually two ways for 
its transmission through content, including direct 
contact and indirect contact. In the indirect contact, 
pathogens spread by the source of COVID-19 virus can 
easily infect the environment and surrounding 
devices, thereby infecting susceptible individuals [4, 
14]. Unlike the SARS virus, the COVID-19 can be 
transmitted during the incubation period [16]. 
Analysis of 22 studies suggests that human viruses 
Table 1. Epidemiological comparison of COVID-19 with MERS and SARS (15 march 2020) 
 
Characterization COVID-19 SARS MERS 
Onset of infection Wuhan, China Guangdong, China Saudi Arabia 
Year of the outbreak 2019- Now 2002-2003 2012 
Primary host Not clear, probably bats Probably cats and bats Probably camel 
Human-to-human 
transmission 
Yes Yes Yes 
Hospital transfer Yes Yes Yes 
Number of countries 
involved 
216 29 27 
Number of cases * 50,586,712 8437 2494 
Mortality rate ~2.5% 11% 34.4% 
 
* Retrieved 8 November 2020 
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such as SARS, MERS, and human coronavirus 
(HCoV) can remain active on non-living surfaces such 
as metal, glass, or plastic for up to 9 days [17]. Also, a 
study reported the probability of transmitting the 
infection through the hospital at 41% from suspected 
patients [18]. 
A small number of patients with COVID-19 have 
reported gastrointestinal symptoms. Also, ACE2 
protein is highly expressed in glandular cells in the 
stomach, duodenum, and rectal epithelium, allowing 
SARS-CoV-2 to enter cells [19]. Researchers also 
detected SARS-CoV-2 RNA from patients’ feces in 
Guangdong, Shenzhen, and the United States. 
According to these researchers, the duration of RNA 
detection in feces is 1 to 12 days [20]. Most 
importantly, while some SARS-CoV-2 infected 
patients experience gastrointestinal symptoms such as 
diarrhea, it has also been revealed that virus can be 
isolated from patients’ urine, testing stool and urine 
samples. In this way, it is possible to remove a potential 
alternative route of transmission, especially through 
health care staff, patients, and so on. Thus, it is 
essential to develop some methods to identify different 
modes of transmission such as stool and urine samples 
to achieve solutions to inhibit or minimize 
transmission and develop methods to control the 
disease [1]. However, isolation of pathogens from feces 
is not necessarily transmission through the fecal-oral 
route, but may also be positive through close contact 
or respiratory infections. There is also no strong 
evidence for the survival time of SARS-CoV-2 in 
different environments [4]. However, the use of 
surface disinfectants such as ethanol, 0.5% hydrogen 
peroxide, or 0.1% sodium hypochlorite for 1 minute 
can effectively inactivate the virus and play a 
significant role in controlling the infection [17]. 
 
4. Virus receptors in the human body 
Analysis of recent studies shows that COVID 19 
binds to the same SARS receptor as the angiotensin-
converting enzyme (ACE2) [13, 21-23]. It has been also 
shown that the surface protein of COVID 19 (S protein) 
has 10 times more affinity than the SARS virus for 
binding to the ACE2 receptor. This result might 
explain the faster transmission of COVID 19 in 
humans than the SARS virus [23]. Expression and 
distribution of ACE2 in the human body may indicate 
possible routes of infection of COVID-19, such as high 
expression of ACE2 in cells of various tissues like lung, 
gastrointestinal tract, heart, kidney, and nasal and oral 
mucosa [24, 25]. In addition to identifying ACE2 as a 
receptor, researchers have found downstream ACE 2 
as an important target for the type II transmembrane 
serine proteases (TMPRSS2), which could be 
considered as a drug design site [11]. In COVID-19, six 
mutation sites have been found that can affect the 
characteristics of the virus transmission and the 
tendency of the virus to bind to cells of various organs. 
In addition to ACE2, other receptors may be involved 
in binding the virus to host cells [11]. 
 
5. Pathogenicity 
The mechanism of pathogenicity of COVID-19 is 
generally unclear and may be affected by various 
organs. COVID-19 enters cells primarily by binding to 
human ACE2. Unlike other beta-coronaviruses, 
primary viral replication is not limited to the upper 
respiratory mucosal epithelium and may occur in 
other organs such as the gastrointestinal tract. Some 
patients also show non-respiratory symptoms such as 
acute inflammation of the liver, heart damage, kidney 
failure, and diarrhea [18, 24, 26]. Attacks on various 
organs result in a complex condition and a variety of 
clinical manifestations, especially in the early stages of 
the disease [27]. Patients infected with COVID-19 
show higher leukocyte counts, abnormal respiratory 
findings, and elevated plasma pro-inflammatory 
cytokine levels [1]. A male case study of a leukopenia 
patient showed a leukocyte count of 2.91 × 109 / L, of 
which 70% were neutrophil. Also, 16 mg C Reactive 
Protein (CRP) was observed in the blood that was 
higher than normal (0-10 mg/l). Increased erythrocyte 
and D-dimer sedimentation were also observed [28]. 
The main pathogenesis of COVID-19 infection as a 
targeted virus of the respiratory system is severe 
pneumonia, viral RNA in the blood, glassy background 
turbidity, and acute heart damage in some cases. 
Increased levels of cytokines and chemokines have 
been observed in patients infected with COVID-19 
including IL1-β, IL1RA, IL7, IL8, IL9, IL10, basic 
FGF2, GCSF, GMCSF, IFNγ, IP10, MCP1, MIP1α, 
MIP1β, PDGFB, TNFα, and VEGFA. Some severe 
cases admitted to the intensive care unit showed high 
levels of pro-inflammatory cytokines including IL2, 
IL7, IL10, GCSF, IP10, MCP1, MIP1α, and TNFα [24].  
Cytokine secretion syndrome is a major cause of 
disease exacerbation and progression. High levels of 
IL-6 and IL-10 have been observed in patients with 
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COVID-19 with increasing the severity of the disease 
[29]. IL-6 and IL-10 are major cytokines that are 
consistently elevated in patients with cytokine 
secretion syndrome. Significant reductions in CD4+T 
cells and CD8+T cells counts have been observed in 
COVID-19 patients [6]. 
 
6. Disease symptoms  
Symptoms of COVID-19 manifest after the 
incubation period (approximately 5.2 days) [13, 16]. 
The onset of symptoms until death is about 6 to 41 
days with a mean period of 14 days. This time depends 
on the immune system conditions and age of patients 
[30]. Various studies have reported the main 
symptoms of the disease as fever, coughing, shortness 
of breath, fatigue, and muscle pain while others have 
also reported sputum, headache, hemoptysis, and 
diarrhea [22, 24, 30, 31]. It is of note that there are 
similarities in symptoms between COVID-19 and 
beta-coronaviruses such as fever, dry coughing, and 
shortness of breath [24]. Nevertheless, COVID-19 has 
some unique clinical characteristics such as lower 
airway involvement and upper respiratory tract 
symptoms such as the runny nose, sneezing, and sore 
throat [32, 33]. 
 
7. Laboratory findings 
In a study conducted on 41 patients in Wuhan, 
China, 63% of patients with lymphopenia and 37% of 
patients with elevated levels of AST enzyme showed an 
increase in high levels of IL2, IL7, and IL10. Moreover, 
compared to non- intensive care unit (ICU) patients, 
ICU patients showed higher levels of IL2, IL7, IL10, 
GSCF, IP10, MCP1, MIP1A, and TNFα. Data analysis 
also showed that the likelihood of having 
lymphopenia, high levels of AST, high levels of D-
dimer, and elevated cardiac enzymes were directly 
associated with the severity of patients and the rate of 
transfer to ICU [24]. In another study conducted on 
123 coronary patients, low levels of CD4+ T cells and 
CD8+ T cells were observed in patients with severe 
pneumonia, but IL-6 and IL-10 levels were higher in 
these patients. Thus, it can be stated that the T cells 
and cytokines can be used as a basis for predicting mild 
to severe disease [29]. 
 
8. Diagnosis  
In a study conducted on 1,014 patients suspected 
of COVID-19, RT-PCR tests and CT imaging of the 
chest were used for the disease diagnosis and 59% and 
88% positive cases were reported, respectively. Using 
RT-PCR as a reference, the sensitivity of CT imaging 
was calculated at 97%. In this study, serial methods of 
these two tests showed that in 60 to 90% of patients, 
the initial CT test was positive before positive RT-PCR. 
Also, in the follow-up of 42% of patients, a CT scan of 
the normal chest before RT- Chest CT was negative. 
Thus, chest CT had a higher sensitivity (not specificity) 
for diagnosing COVID-19 compared to RT-PCR from 
swab samples in the Chinese epidemic area [34]. In 
another research, 49 out of 51 patients with COVID 19, 
confirmed by molecular tests, had a positive CT test 
(96.1%). For this reason, this study recommended that 
CT imaging may be useful as a standard method for 
the rapid diagnosis of COVID 19 to optimize patient 
management (28). In another study, the sensitivity of 
CT imaging was reported to be 95% based on clinical 
findings. Also, it was found that CT imaging could 
reduce cases of false-negative nucleic acid testing [22]. 
However, the final confirmation of patients includes 
RT-PCR real-time PCR or sequencing of viral genes in 
respiratory or blood samples [16]. 
 
9. Treatment and prevention 
There is no specific antiviral drug or vaccine 
against COVID 19 infection for possible treatment and 
prevention in humans. The only available option is to 
use broad-spectrum antiviral drugs such as nucleoside 
analogs and HIV-protease inhibitors, which can 
weaken virus infection until a specific antivirus is 
available [35, 36].  Some of the antiviral drugs used to 
treat these patients include oseltamivir, lopinavir, 
ganciclovir, and ritonavir [37]. Another study reported 
that the broad-spectrum antiviral drugs of Remdesivir 
and chloroquine were very effective in controlling 
COVID-19 infection in vitro [26]. Moreover, a 
laboratory study and a clinical study showed that 
Remdesivir (which is a new nucleotide analog) and 
adenosine analog (which acts as a viral protein 
inhibitor) improved one patient [38, 39]. The Chinese 
National Health Commission states that Tocilizumab 
(Actemra) can treat COVID-19 patients who have 
severe lung damage and high levels of IL-6. This drug 
applies its effect by inhibiting high levels of protein 
interleukin-6, which can cause inflammation [40]. 
Although the treatment of some cases with interferon 
inhalation showed no clinical effect, it worsened the 
condition as pulmonary turbidity progresses [28]. 
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However, more studies are needed to identify new 
therapeutic drugs to treat COVID-19 infection. Many 
scientists are currently trying to develop a non-human 
model for studying COVID-19 infection for rapid 
treatment and testing of potential vaccines, as well as 
providing a better understanding of virus-host 
interaction [1]. 
 
10. Iranian experiences at a glance 
Between 20 February 2020 and 2 April 2020, a 
hospital based-study study was conducted in one of 
the first and largest hospital that was specifically 
designated for the hospitalization of individuals with 
suspected COVID-19 in Tehran (Capital of Iran). Their 
findings showed that of 1,061 suspected patients, 570 
patients had RT-PCR positive results and confirmed as 
a COVID-19 infection. Among them, 15.6% patients 
died (with a median age of 64 years), and 4.4% were 
referred to the ICUs. The median (IQR) age of these 
patients was 56.5 (45–66) years and approximately 
65% were male [41]. Another study in above 
mentioned hospital 231 suspected cases of COVID-19 
were studied during two weeks. Of which 31.2% were 
confirmed as a COVID-19 cases by RT-PCR and 
admitted to ICU with different level of acute 
respiratory distress syndrome (ARDS). In overall, 25% 
of ARDS cases were died over two weeks. Different 
therapeutic regimens were employed for these 
patients including the use of oxygen therapy, 
supplementation (vitamin D3, thiamine, and 
selenium), steroid therapy, immunoglobulin therapy, 
and interferon beta-1a and Ribavirin combination 
[42]. Ghanbari on forecasting the spread of the 
COVID-19 in Iran, predict that the second wave will be 
more challenging and is predicated to happen between 
August and December 2020 [43]. 
 
11. Conclusion 
 Based on the studies and experiences mentioned 
in this article, the following recommendations are 
presented: 1) preventing and controlling the infection, 
observing personal and public health, quarantining 
suspicious and sick people, and not traveling and 2) 
using CT scan technique to diagnose patients, followed 
by using molecular tests for confirmation. In general, 
the diagnosis of the virus in many organs complicates 
the determination of the source and route of 
transmission of the new coronary pneumonia and 
increases the risk of transmission. Major gaps in our 
knowledge on the origin, epidemiology, and duration 
of human transmission and clinical spectrum of the 
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